Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
2
40%
Ph not_applicable
2
40%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(1)
Terminated(2)
Other(2)

Detailed Status

unknown2
Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 32 (40.0%)
N/A2 (40.0%)

Trials by Status

completed120%
unknown240%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

NCT04725331
unknownnot_applicable

Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy

NCT05266625
unknownnot_applicable

A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus

NCT05302050
terminatedphase_3

Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes

NCT05094401
completedphase_3

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

NCT04886388

Clinical Trials (5)

Showing 5 of 5 trials
NCT04725331Phase 1

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Terminated
NCT05266625Not Applicable

Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy

Unknown
NCT05302050Not Applicable

A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus

Unknown
NCT05094401Phase 3

Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes

Terminated
NCT04886388Phase 3

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Completed

All 5 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
5